ZA200501084B - Dispersible tablets for oral administration - Google Patents
Dispersible tablets for oral administrationInfo
- Publication number
- ZA200501084B ZA200501084B ZA200501084A ZA200501084A ZA200501084B ZA 200501084 B ZA200501084 B ZA 200501084B ZA 200501084 A ZA200501084 A ZA 200501084A ZA 200501084 A ZA200501084 A ZA 200501084A ZA 200501084 B ZA200501084 B ZA 200501084B
- Authority
- ZA
- South Africa
- Prior art keywords
- oral administration
- dispersible tablets
- dispersible
- tablets
- oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN753DE2002 | 2002-07-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200501084B true ZA200501084B (en) | 2006-03-29 |
Family
ID=30012265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200501084A ZA200501084B (en) | 2002-07-16 | 2006-01-24 | Dispersible tablets for oral administration |
Country Status (10)
Country | Link |
---|---|
US (1) | US20060110445A1 (es) |
EP (1) | EP1539146A1 (es) |
KR (1) | KR20050062514A (es) |
CN (1) | CN1681497A (es) |
AU (1) | AU2003249116A1 (es) |
BR (1) | BR0312728A (es) |
EA (1) | EA200500213A1 (es) |
MX (1) | MXPA05000641A (es) |
WO (1) | WO2004006917A1 (es) |
ZA (1) | ZA200501084B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI21912A (sl) * | 2004-12-24 | 2006-06-30 | Lek Farmacevtska Druzba D.D. | Stabilne farmacevtske oblike, ki vsebujejo amoksicilin in klavulansko kislino |
WO2007058397A1 (en) * | 2005-11-17 | 2007-05-24 | Gl Pharmtech Corp. | A dispersible tablet comprising the mixture of amoxicillin and clavulanic acid or its salts and processes for preparing the same |
TR201002878A2 (tr) * | 2010-04-13 | 2011-10-21 | Bi̇lgi̇ç Mahmut | Sefpodoksim proksetil içeren farmasötik bileşimler. |
EP2575777A1 (en) * | 2010-06-03 | 2013-04-10 | Mahmut Bilgic | Formulation comprising cefpodoxime proxetil and clavulanic acid |
TR201007106A1 (tr) * | 2010-08-25 | 2012-03-21 | Bi̇lgi̇ç Mahmut | Sefpodoksim proksetil formülasyonları. |
TR201007107A1 (tr) * | 2010-08-25 | 2012-03-21 | Bi̇lgi̇ç Mahmut | Tat düzenleyici ajan içeren sefpodoksim proksetil formülasyonları. |
TR201009167A2 (tr) * | 2010-11-05 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Sefalosporin içeren farmasötik granüller. |
TR201009168A2 (tr) * | 2010-11-05 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Suda dağılan sefpodoksim proksetil formülasyonları. |
TR201010860A2 (tr) * | 2010-11-05 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Sefdinir formulasyonları için üretim yöntemi. |
WO2013001543A1 (en) * | 2011-06-30 | 2013-01-03 | Aggarwal Kumar Vijay | An optimized bilayered tablet dosage form with two active antibiotics: clavulanic acid and cefpodoxime |
WO2013001541A1 (en) * | 2011-06-30 | 2013-01-03 | Aggarwal Kumar Vijay | An optimized bilayered tablet dosage form with high rate of bioavailability of two active antibiotics: cefuroxime and clavulanic acid |
CN102488668A (zh) * | 2011-12-29 | 2012-06-13 | 山东淄博新达制药有限公司 | 头孢呋辛酯分散片剂及其制备方法 |
CN102697747A (zh) * | 2012-06-13 | 2012-10-03 | 广州南新制药有限公司 | 一种头孢呋辛酯的分散片 |
EP2882423A1 (en) * | 2012-08-07 | 2015-06-17 | Sandoz AG | Uncoated tablet comprising granules including a -lactam antibiotic and highly dispersed silicone dioxide |
CN103340855B (zh) * | 2013-07-16 | 2015-01-07 | 上海汉维生物医药科技有限公司 | 复方阿莫西林克拉维酸钾片剂及其制备方法 |
CN104546838B (zh) * | 2013-07-16 | 2018-05-01 | 上海汉维生物医药科技有限公司 | 片剂及其制备方法 |
CN104473922B (zh) * | 2013-07-16 | 2018-05-01 | 上海汉维生物医药科技有限公司 | 复方片剂及其制备方法 |
WO2015070131A1 (en) * | 2013-11-11 | 2015-05-14 | Forest Laboratories Holdings Limited | Compositions and methods of treatment comprising fosfomycin disodium |
CN104257618B (zh) * | 2014-09-26 | 2017-01-11 | 山东新时代药业有限公司 | 一种含有法罗培南钠的口腔崩解片及其制备方法 |
CN113398083A (zh) * | 2021-06-24 | 2021-09-17 | 山东淄博新达制药有限公司 | 一种头孢呋辛酯分散片及其制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1552416A (en) * | 1975-08-12 | 1979-09-12 | Beecham Group Ltd | Pharmaceutical compositions |
GB8628359D0 (en) * | 1986-11-27 | 1986-12-31 | Zyma Sa | Galenical formulation |
EP0281200B1 (en) * | 1987-03-02 | 1994-01-19 | Yamanouchi Europe B.V. | Pharmaceutical composition, pharmaceutical granulate and process for their preparation |
GB9109862D0 (en) * | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
US5698226A (en) * | 1993-07-13 | 1997-12-16 | Glaxo Wellcome Inc. | Water-dispersible tablets |
US6361794B1 (en) * | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
US5837292A (en) * | 1996-07-03 | 1998-11-17 | Yamanouchi Europe B.V. | Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug |
CN1194687C (zh) * | 1997-02-14 | 2005-03-30 | 史密斯克莱恩比彻姆药物实验室 | 含有阿莫西林和克拉维酸盐的药物制剂 |
US5955107A (en) * | 1997-12-12 | 1999-09-21 | Fmc Corporation | Pharmaceutical suspension tablet compositions |
AU1232500A (en) * | 1998-10-30 | 2000-05-22 | Fuisz International Ltd. | Improved amoxycillin and clavulanate composition |
CA2393614C (en) * | 2002-07-19 | 2003-09-30 | Abbott Laboratories | Antibacterial clarithromycin compositions and processes for making the same |
-
2003
- 2003-07-16 WO PCT/IB2003/002817 patent/WO2004006917A1/en not_active Application Discontinuation
- 2003-07-16 EP EP03764046A patent/EP1539146A1/en not_active Withdrawn
- 2003-07-16 AU AU2003249116A patent/AU2003249116A1/en not_active Abandoned
- 2003-07-16 BR BR0312728-1A patent/BR0312728A/pt not_active Application Discontinuation
- 2003-07-16 CN CNA038214539A patent/CN1681497A/zh active Pending
- 2003-07-16 MX MXPA05000641A patent/MXPA05000641A/es not_active Application Discontinuation
- 2003-07-16 KR KR1020057000710A patent/KR20050062514A/ko not_active Application Discontinuation
- 2003-07-16 US US10/521,423 patent/US20060110445A1/en not_active Abandoned
- 2003-07-16 EA EA200500213A patent/EA200500213A1/ru unknown
-
2006
- 2006-01-24 ZA ZA200501084A patent/ZA200501084B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
BR0312728A (pt) | 2005-04-26 |
CN1681497A (zh) | 2005-10-12 |
MXPA05000641A (es) | 2005-04-19 |
KR20050062514A (ko) | 2005-06-23 |
AU2003249116A1 (en) | 2004-02-02 |
US20060110445A1 (en) | 2006-05-25 |
EA200500213A1 (ru) | 2005-08-25 |
WO2004006917A1 (en) | 2004-01-22 |
EP1539146A1 (en) | 2005-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200501084B (en) | Dispersible tablets for oral administration | |
EG25453A (en) | Deferacirox dispersible tablets | |
HK1081457A1 (en) | Dispersible pharmaceutical compositions | |
HK1085131A1 (en) | Solid drug for oral use | |
IL164519A0 (en) | Pharmaceutical formulations | |
AU3574500A (en) | Rapidly disintegrable tablet for oral administration | |
EP1553925A4 (en) | ORAL DOSAGE FORM WITH MODIFIED RELEASE | |
PL364621A1 (en) | Nicotine-containing oral dosage form | |
PT1362582E (pt) | Forma de dosagem sólida revestida | |
HUP0400850A3 (en) | Oral pharmaceutical compositions | |
IL166337A0 (en) | Oral administration of calctionin | |
GB0209668D0 (en) | Oral devices | |
GB2392093B (en) | Pharmaceutical formulations | |
HUP0500638A3 (en) | Flashmelt oral dosage formulation | |
HK1072194A1 (en) | Oral dosage form for controlled drug release | |
IL162510A0 (en) | Pharmaceutical suspension for oral administration | |
HUP0401599A3 (en) | Extended release oral dosage form | |
EP1357898A4 (en) | ORAL DOSAGE FORM WITH ENHANCED REGULATED RELEASE | |
AU2003244092A1 (en) | 1ss-METHYLCARBAPENEM DERIVATIVE FOR ORAL ADMINISTRATION | |
EP1491189A4 (en) | ORAL PHARMACEUTICALS WITH DICLOFENAC SODIUM | |
ZA200204905B (en) | Improved pharmaceutical dental formulations. | |
IL165843A0 (en) | Popping oral administration form | |
SG103334A1 (en) | Tablet for oral administration comprising 2-[(4-methoxy-2-methyl)-2-pyridinyl]methylsulfinyl-5-(1h-pyrrol-1-yl)-1h-benzimidazole | |
GB0218994D0 (en) | Oral pharmaceutical compositions | |
AU2003238900A8 (en) | Pharmaceutical formulation |